STAT - Reporting from the frontiers of health and medicine

Special Report

Special Report

Politics

Politics Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm
Health Tech ‘It’s hard to know what’s trustworthy’: A new research effort aims to vet digital health data from wearables
Health STAT+ Conversations: Can tech change in-home care for seniors?
Pharma Drug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them?
First Opinion FDA should lead the way on new ALS treatments, not Canada and Europe

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

Pear Therapeutics to go public in $1.6 billion SPAC merger
Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between
HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies

Health

By Erika Check Hayden

Prescription Politics

Special Report

Special Report

Health

Health Tech

Special Report Chadwick Boseman’s tragedy is America’s tragedy: In colorectal cancer hot spots, young men are dying at higher rates
Health Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson
Health Tech ‘Nobody is catching it’: Algorithms used in health care nationwide are rife with bias
Special Report Watch: An unusual 30th birthday gift: Why I got a colonoscopy so young — and documented every step
Special Report The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race
Health Tech A popular algorithm to predict sepsis misses most cases and sends frequent false alarms, study finds
Politics Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm
Health How the Covid pandemic ends: Scientists look to the past to see the future